中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

159 records (took 0.02 seconds)

    FGF2 TRUNCATIONS AND MUTANTS AND USES THEREOF
    2.
    发明申请
    FGF2 TRUNCATIONS AND MUTANTS AND USES THEREOF 审中-公开
    FGF2截短和突变及其用途

    公开(公告)号：WO2016100820A3

    公开(公告)日：2016-11-03

    申请号：PCT/US2015066683

    申请日：2015-12-18

    Applicant: SALK INST FOR BIOLOGICAL STUDI

    Inventor： EVANS RONALD M ,  DOWNES MICHAEL ,  ATKINS ANNETTE ,  SUH JAE MYOUNG ,  YU RUTH T

    IPC: A61K38/18 ,  C07K14/50 ,  C07K19/00

    CPC classification number: C07K14/503 ,  A61K38/1825

    Abstract: The present disclosure provides FGF2 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Thus, the disclosed mutant FGF2 proteins can be used to treat one or more metabolic diseases. In some examples, mutant FGF2 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels, for example to treat a metabolic disorder are also provided.

    Abstract translation: 本公开提供了FGF2突变蛋白，例如具有N端缺失，点突变或其组合的FGF2突变蛋白，其可以降低哺乳动物的血糖。 因此，所公开的突变FGF2蛋白可以用于治疗一种或多种代谢疾病。 在一些例子中，突变FGF2蛋白具有降低的促有丝分裂活性。 还提供了编码这种蛋白质的核酸分子，以及包含这种核酸的载体和细胞。 还提供了使用公开的分子降低血糖水平的方法，例如用于治疗代谢病症。

    CHIMERIC FIBROBLAST GROWTH FACTOR (FGF) 2/FGF1 PEPTIDES AND METHODS OF USE
    4.
    发明申请
    CHIMERIC FIBROBLAST GROWTH FACTOR (FGF) 2/FGF1 PEPTIDES AND METHODS OF USE 审中-公开
    CHIMERIC FIBROBLAST GROWTH FACTOR（FGF）2 / FGF1 PEPTIDES AND METHODS OF USE

    公开(公告)号：WO2015061351A1

    公开(公告)日：2015-04-30

    申请号：PCT/US2014/061624

    申请日：2014-10-21

    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES

    Inventor： SUH, Jae, Myoung ,  DOWNES, Michael ,  EVANS, Ronald, M. ,  ATKINS, Annette

    IPC: C07K14/50 ,  C07K19/00 ,  A61K38/18 ,  A61P3/08 ,  A61P3/04

    CPC classification number: C07K14/503 ,  A61K38/00 ,  A61K38/1825 ,  A61K45/06 ,  C07K14/501 ,  C07K2319/00

    Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein. Such FGF2/FGF1 chimeras can further include a fibroblast growth factor receptor (FGFR) lc-binding protein, a β-Klotho-binding protein, or both. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.

    Abstract translation: 本公开提供具有与C-末端偶联的N-末端的嵌合蛋白，其中N末端包含成纤维细胞生长因子（FGF）2的N末端部分，并且C末端包含FGF1蛋白的一部分。 这样的FGF2 / FGF1嵌合体可以进一步包括成纤维细胞生长因子受体（FGFR）结合蛋白，β-Klotho结合蛋白或两者。 还提供了编码这种蛋白质的核酸分子，以及包括这种核酸的载体和细胞。 还提供了使用所公开的分子降低血糖水平的方法。

    THERMOSTABLE VARIANTS OF FIBROBLAST GROWTH FACTORS
    6.
    发明申请
    THERMOSTABLE VARIANTS OF FIBROBLAST GROWTH FACTORS 审中-公开
    纤维生长因子的可变温度变异

    公开(公告)号：WO2012158244A3

    公开(公告)日：2013-01-24

    申请号：PCT/US2012027310

    申请日：2012-03-01

    Applicant: HUMANZYME INC ,  JEONG SOON SEOG

    Inventor： JEONG SOON SEOG

    IPC: C12N15/12 ,  C12N5/02 ,  C12N5/0735

    CPC classification number: C07K14/503 ,  C12N5/0606

    Abstract: The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.

    Abstract translation: 本技术涉及工程改造的人成纤维细胞生长因子-2（FGF2）蛋白及其使用方法。 特别地，所述方法和组合物涉及与野生型蛋白相比具有增加的热稳定性的FGF2突变体以及在培养胚胎干细胞中使用蛋白质的方法。

    SUBSTANCES AND METHODS FOR THE TREATMENT OF LYSOSMAL STORAGE DISEASES
    7.
    发明申请
    SUBSTANCES AND METHODS FOR THE TREATMENT OF LYSOSMAL STORAGE DISEASES 审中-公开
    用于治疗病理性存活疾病的物质和方法

    公开(公告)号：WO2011073199A1

    公开(公告)日：2011-06-23

    申请号：PCT/EP2010/069649

    申请日：2010-12-14

    Applicant: STEINFELD, Robert

    Inventor： STEINFELD, Robert

    IPC: C12N15/62 ,  C07K14/50 ,  C12N9/48

    CPC classification number: C07K14/503 ,  A61K38/00 ,  C07K2319/00 ,  C12N9/48 ,  C12Y304/14009

    Abstract: The present invention relates to a chimeric molecule comprising (i) a targeting moiety that binds to heparin or heparan sulfate proteoglycans, (ii) a lysosomal peptide or protein, (iii) wherein the targeting moiety is a neurotrophic growth factor and/or, wherein the targeting moiety comprises one of the following consensus sequences BBXB, BXBB, BBXXB, BXXBB, BBXXXB or BXXXBB and wherein B represents an arginine, lysine or histidine amino acid and X represents any amino acid, (iii) with the proviso that the targeting moiety is at least thirteen amino acids long.

    Abstract translation: 本发明涉及嵌合分子，其包含（i）结合肝素或硫酸乙酰肝素蛋白聚糖的靶向部分，（ii）溶酶体肽或蛋白质，（iii）其中靶向部分是神经营养生长因子和/或其中 靶向部分包含以下共有序列BBXB，BXBB，BBXXB，BXXBB，BBXXXB或BXXXBB之一，其中B表示精氨酸，赖氨酸或组氨酸氨基酸，X表示任何氨基酸，（iii）条件是靶向部分 至少十三个氨基酸长。

    USE OF A PEPTIDE AS A THERAPEUTIC AGENT
    9.
    发明申请
    USE OF A PEPTIDE AS A THERAPEUTIC AGENT 审中-公开
    使用作为治疗剂的肽

    公开(公告)号：WO2009040034A3

    公开(公告)日：2009-07-23

    申请号：PCT/EP2008007743

    申请日：2008-09-09

    Applicant: MONDOBIOTECH LAB AG ,  BEVEC DORIAN ,  CAVALLI FABIO ,  CAVALLI VERA ,  BACHER GERALD

    Inventor： BEVEC DORIAN ,  CAVALLI FABIO ,  CAVALLI VERA ,  BACHER GERALD

    IPC: A61K38/08 ,  A61K38/31 ,  A61P3/00 ,  A61P9/00 ,  A61P11/00 ,  A61P25/28 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K14/503

    Abstract: The present invention is directed to the use of the peptide compound Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    Abstract translation: 本发明涉及肽化合物Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH作为预防和/或治疗癌症，自身免疫性疾病，纤维化疾病，炎症性疾病 疾病，神经退行性疾病，传染病，肺部疾病，心血管疾病和代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH的母乳代用品的药物组合物， 至少一种药学上可接受的载体，低温保护剂，冻干保护剂，赋形剂和/或稀释剂。

Patent Agency Ranking